Cargando…

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer

Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI, however, robust markers to predict therapy response are missing. Here we show that blood platelets interact with lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hinterleitner, Clemens, Strähle, Jasmin, Malenke, Elke, Hinterleitner, Martina, Henning, Melanie, Seehawer, Marco, Bilich, Tatjana, Heitmann, Jonas, Lutz, Martina, Mattern, Sven, Scheuermann, Sophia, Horger, Marius, Maurer, Stefanie, Walz, Juliane, Fend, Falko, Handgretinger, Rupert, Seitz, Christian, Weigelin, Bettina, Singer, Stephan, Salih, Helmut, Borst, Oliver, Kopp, Hans-Georg, Zender, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636618/ https://www.ncbi.nlm.nih.gov/pubmed/34853305 http://dx.doi.org/10.1038/s41467-021-27303-7

Ejemplares similares

Long‐term remission of small cell lung cancer after reactivation of tuberculosis following immune‐checkpoint blockade: A case report
por: Sirgiovanni, Mattia, et al.
Publicado: (2021)

NUT Carcinoma—An Underdiagnosed Malignancy
por: Lauer, Ulrich M., et al.
Publicado: (2022)

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression
por: Rittig, Susanne M., et al.
Publicado: (2022)

Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report
por: Stingu, Elena, et al.
Publicado: (2023)

Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression
por: Hinterleitner, Clemens, et al.
Publicado: (2021)

NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma
por: Schmidt, Moritz, et al.
Publicado: (2023)

Early Reconstitution of Antibody Secreting Cells after Allogeneic Stem Cell Transplantation
por: Hinterleitner, Martina, et al.
Publicado: (2022)

Inflammatory Surrogate Parameters for Predicting Ifosfamide-Induced Neurotoxicity in Sarcoma Patients
por: Schmidt, Moritz, et al.
Publicado: (2022)

Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
por: Schmidt, Moritz, et al.
Publicado: (2023)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
por: Hagelstein, Ilona, et al.
Publicado: (2021)

Platelet-expressed immune checkpoint regulator GITRL in breast cancer
por: Zhou, Yanjun, et al.
Publicado: (2021)

Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies
por: Hinterleitner, Martina, et al.
Publicado: (2021)

Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?
por: Zhou, Yanjun, et al.
Publicado: (2021)

PD-L1 and intratumoral immune response in breast cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2017)

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options
por: Bitzer, Michael, et al.
Publicado: (2020)

Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol
por: Werner, Sebastian, et al.
Publicado: (2020)

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
por: Rasmussen, Jacob H., et al.
Publicado: (2019)

Extended Texture Analysis of Non-Enhanced Whole-Body MRI Image Data for Response Assessment in Multiple Myeloma Patients Undergoing Systemic Therapy
por: Ekert, Kaspar, et al.
Publicado: (2020)

DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis
por: Chashchina, Anna, et al.
Publicado: (2021)

EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes
por: De Rosa, Simona, et al.
Publicado: (2018)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma
por: Erlmeier, F., et al.
Publicado: (2016)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

Genetic dissection of intratumor heterogeneity of PD‐L1 expression in EGFR ‐mutated lung adenocarcinoma
por: Kunimasa, Kei, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer
por: Calik, Ilknur, et al.
Publicado: (2019)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis
por: Müller, T., et al.
Publicado: (2021)

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023)

Identification of CD318 (CDCP1) as novel prognostic marker in AML
por: Heitmann, Jonas S., et al.
Publicado: (2020)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l6n6knjcvvutat0u03ujsth1j8